Xiaflex Sales Still Slow, But Other Indications In The Works
This article was originally published in The Pink Sheet Daily
Auxilium’s Xiaflex sales still languish, but its older testosterone product continues to drive growth for the company.
You may also be interested in...
Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.
The acquisition will establish Auxilium as a leading urology company and add nine commercial products. But the $585 million upfront acquisition price is expensive for Auxilium, as sales of its own products slump.
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.